vs
Side-by-side financial comparison of Forestar Group Inc. (FOR) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $273.0M, roughly 1.2× Forestar Group Inc.). HAEMONETICS CORP runs the higher net margin — 13.2% vs 5.6%, a 7.6% gap on every dollar of revenue. On growth, Forestar Group Inc. posted the faster year-over-year revenue change (9.0% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-157.1M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -9.6%).
Forestar Group Inc. is a residential lot development company based in Arlington, Texas. The company has operations in 51 markets in 21 states and delivered 11,518 residential lots during the twelve-month period ended December 31, 2020. The company is publicly traded on the New York Stock Exchange and in October 2017 became a majority-owned subsidiary of D.R. Horton, Inc., the largest homebuilder by volume in the United States since 2002. The company primarily acquires entitled real estate and...
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
FOR vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $273.0M | $339.0M |
| Net Profit | $15.4M | $44.7M |
| Gross Margin | 20.1% | 59.7% |
| Operating Margin | 7.6% | 19.9% |
| Net Margin | 5.6% | 13.2% |
| Revenue YoY | 9.0% | -2.7% |
| Net Profit YoY | -6.7% | 19.3% |
| EPS (diluted) | $0.30 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $273.0M | $339.0M | ||
| Q3 25 | $670.5M | $327.3M | ||
| Q2 25 | $390.5M | $321.4M | ||
| Q1 25 | $351.0M | $330.6M | ||
| Q4 24 | $250.4M | $348.5M | ||
| Q3 24 | $551.3M | $345.5M | ||
| Q2 24 | $318.4M | $336.2M | ||
| Q1 24 | $333.8M | — |
| Q4 25 | $15.4M | $44.7M | ||
| Q3 25 | $86.9M | $38.7M | ||
| Q2 25 | $32.9M | $34.0M | ||
| Q1 25 | $31.6M | $58.0M | ||
| Q4 24 | $16.5M | $37.5M | ||
| Q3 24 | $81.5M | $33.8M | ||
| Q2 24 | $38.7M | $38.4M | ||
| Q1 24 | $45.0M | — |
| Q4 25 | 20.1% | 59.7% | ||
| Q3 25 | 22.3% | 59.5% | ||
| Q2 25 | 20.4% | 59.8% | ||
| Q1 25 | 22.6% | 58.4% | ||
| Q4 24 | 22.0% | 55.5% | ||
| Q3 24 | 23.9% | 54.2% | ||
| Q2 24 | 22.5% | 52.0% | ||
| Q1 24 | 24.9% | — |
| Q4 25 | 7.6% | 19.9% | ||
| Q3 25 | 16.9% | 17.9% | ||
| Q2 25 | 11.2% | 16.8% | ||
| Q1 25 | 11.6% | 21.6% | ||
| Q4 24 | 8.7% | 16.9% | ||
| Q3 24 | 19.7% | 15.0% | ||
| Q2 24 | 16.2% | 11.8% | ||
| Q1 24 | 17.6% | — |
| Q4 25 | 5.6% | 13.2% | ||
| Q3 25 | 13.0% | 11.8% | ||
| Q2 25 | 8.4% | 10.6% | ||
| Q1 25 | 9.0% | 17.5% | ||
| Q4 24 | 6.6% | 10.8% | ||
| Q3 24 | 14.8% | 9.8% | ||
| Q2 24 | 12.2% | 11.4% | ||
| Q1 24 | 13.5% | — |
| Q4 25 | $0.30 | $0.95 | ||
| Q3 25 | $1.70 | $0.81 | ||
| Q2 25 | $0.65 | $0.70 | ||
| Q1 25 | $0.62 | $1.17 | ||
| Q4 24 | $0.32 | $0.74 | ||
| Q3 24 | $1.59 | $0.66 | ||
| Q2 24 | $0.76 | $0.74 | ||
| Q1 24 | $0.89 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $211.7M | $363.4M |
| Total DebtLower is stronger | $793.2M | $1.2B |
| Stockholders' EquityBook value | $1.8B | $911.5M |
| Total Assets | $3.2B | $2.5B |
| Debt / EquityLower = less leverage | 0.44× | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $211.7M | $363.4M | ||
| Q3 25 | $379.2M | $296.4M | ||
| Q2 25 | $189.2M | $292.9M | ||
| Q1 25 | $174.3M | $306.8M | ||
| Q4 24 | $132.0M | $320.8M | ||
| Q3 24 | $481.2M | $299.3M | ||
| Q2 24 | $359.2M | $344.4M | ||
| Q1 24 | $416.2M | — |
| Q4 25 | $793.2M | $1.2B | ||
| Q3 25 | $802.7M | $1.2B | ||
| Q2 25 | $872.8M | $1.2B | ||
| Q1 25 | $872.5M | $1.2B | ||
| Q4 24 | $806.8M | — | ||
| Q3 24 | $706.4M | — | ||
| Q2 24 | $706.1M | — | ||
| Q1 24 | $705.7M | — |
| Q4 25 | $1.8B | $911.5M | ||
| Q3 25 | $1.8B | $849.2M | ||
| Q2 25 | $1.7B | $882.3M | ||
| Q1 25 | $1.6B | $820.8M | ||
| Q4 24 | $1.6B | $906.9M | ||
| Q3 24 | $1.6B | $878.9M | ||
| Q2 24 | $1.5B | $905.4M | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $3.2B | $2.5B | ||
| Q3 25 | $3.1B | $2.4B | ||
| Q2 25 | $3.1B | $2.5B | ||
| Q1 25 | $3.0B | $2.5B | ||
| Q4 24 | $3.0B | $2.5B | ||
| Q3 24 | $2.8B | $2.5B | ||
| Q2 24 | $2.7B | $2.5B | ||
| Q1 24 | $2.6B | — |
| Q4 25 | 0.44× | 1.34× | ||
| Q3 25 | 0.45× | 1.44× | ||
| Q2 25 | 0.52× | 1.39× | ||
| Q1 25 | 0.53× | 1.49× | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.48× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-157.0M | $93.6M |
| Free Cash FlowOCF − Capex | $-157.1M | $87.2M |
| FCF MarginFCF / Revenue | -57.5% | 25.7% |
| Capex IntensityCapex / Revenue | 0.0% | 1.9% |
| Cash ConversionOCF / Net Profit | -10.19× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $93.0M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-157.0M | $93.6M | ||
| Q3 25 | $256.3M | $111.3M | ||
| Q2 25 | $15.8M | $17.4M | ||
| Q1 25 | $-19.8M | $116.6M | ||
| Q4 24 | $-450.0M | $43.8M | ||
| Q3 24 | $119.2M | $48.8M | ||
| Q2 24 | $-61.7M | $-27.4M | ||
| Q1 24 | $-59.2M | — |
| Q4 25 | $-157.1M | $87.2M | ||
| Q3 25 | $255.6M | $106.3M | ||
| Q2 25 | $15.0M | $13.6M | ||
| Q1 25 | $-20.5M | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | $118.4M | $39.4M | ||
| Q2 24 | $-62.3M | $-33.1M | ||
| Q1 24 | $-59.8M | — |
| Q4 25 | -57.5% | 25.7% | ||
| Q3 25 | 38.1% | 32.5% | ||
| Q2 25 | 3.8% | 4.2% | ||
| Q1 25 | -5.8% | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | 21.5% | 11.4% | ||
| Q2 24 | -19.6% | -9.8% | ||
| Q1 24 | -17.9% | — |
| Q4 25 | 0.0% | 1.9% | ||
| Q3 25 | 0.1% | 1.5% | ||
| Q2 25 | 0.2% | 1.2% | ||
| Q1 25 | 0.2% | 4.7% | ||
| Q4 24 | 0.0% | 2.5% | ||
| Q3 24 | 0.1% | 2.7% | ||
| Q2 24 | 0.2% | 1.7% | ||
| Q1 24 | 0.2% | — |
| Q4 25 | -10.19× | 2.09× | ||
| Q3 25 | 2.95× | 2.88× | ||
| Q2 25 | 0.48× | 0.51× | ||
| Q1 25 | -0.63× | 2.01× | ||
| Q4 24 | -27.27× | 1.17× | ||
| Q3 24 | 1.46× | 1.44× | ||
| Q2 24 | -1.59× | -0.71× | ||
| Q1 24 | -1.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOR
| D.R.Horton Inc. | $183.8M | 67% |
| Other | $89.2M | 33% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
